

Global Microbiome Therapeutics Market: Focus on Target Therapies, Region (10 Countries), and Competitive Landscape - Analysis and Forecast, 2019-2030

<https://marketpublishers.com/r/GB204D360582EN.html>

Date: December 2020

Pages: 149

Price: US\$ 5,000.00 (Single User License)

ID: GB204D360582EN

Abstracts

Hard copy option is available on any of the options above at an additional charge of \$500. Please email us at order@marketpublishers.com with your request.

Market Report Coverage - Microbiome Therapeutics

Market Segmentation

By Disease Type: Gastrointestinal and Infectious Diseases and Other Diseases

By Region: North America, Europe, Asia-Pacific, and Rest-of-the-World

Regional Segmentation

North America – U.S., Canada

Europe – Germany, U.K., France, Sweden, and Rest-of-Europe

Asia-Pacific – China, Australia, Japan, India, and Rest-of-Asia-Pacific

Rest-of-the-World

Growth Drivers

Global Microbiome Therapeutics Market: Focus on Target Therapies, Region (10 Countries), and Competitive Lands...

Increasing adoption of inorganic growth strategies in the market

Significant external funding for executing research and therapeutic innovation

Market Challenges

Payer uncertainty and outcome-based pricing

Insufficient Application-Based Research Hindering Market Pull

Market Opportunities

Entry of major players for the development of microbiome therapeutics

Growing eminence of microbiome therapeutics in cancer treatment

Key Microbiome Therapeutics Companies Profiled

4D PHARMA PLC, AOBIOME, SANOFI S.A, FERRING PHARMACEUTICALS, FINCH THERAPEUTICS, IMMURON LIMITED, OXTERA AB, AMONG OTHERS

Key Questions Answered in this Report:

What is microbiome therapeutics? How have different target therapy area settings for microbiome therapeutics evolved over the centuries?

What are the major market drivers, challenges, and opportunities in the global microbiome therapeutics market?

What was the global microbiome therapeutics market size in terms of revenue in 2019? How is the market expected to evolve in the upcoming years? What is the expected market size in 2030?

How is each segment of the global microbiome therapeutics market expected to

grow during the forecast period 2020-2030, and what is the estimated revenue expected to be generated by each of the segments by the end of 2030?

What are the developmental strategies implemented by the key players to sustain in the competitive market?

What is the growth potential of the global microbiome therapeutics in several countries globally?

Which target therapy area segment among the two gastrointestinal and infectious diseases and other therapy areas are offered or being developed by key players such as Taisho Pharmaceuticals, Immuron Limited, Sanofi S.A., and Rebiotix?

Which target therapy area segment led the market in 2019 and is expected to dominate the market in 2030, and why?

Which region dominated the global microbiome therapeutics market in 2019, and what are the anticipated trends from each of the regions in the forecast period 2020-2030?

Market Overview

Microbiome is defined as the collective genomes of the microbes (composed of fungi, bacteria, bacteriophage, viruses, and protozoa) that live inside and on the body.

Clinical studies on various microbiomes have been significantly growing during the past decade, owing to the considerable reduction in the cost of DNA sequencing, enabling the microbes in their complex mixture to be defined by their genome. Research findings have generated information about the role of the microorganism population in determining human health. The microbiome is found to play a role in inflammatory bowel disease (IBD), allergies, and immune-oncology, among others. Microbiome has become an attractive target for potential therapeutics owing to its extensive role in gastrointestinal and non-gastrointestinal diseases. However, there are challenges associated with microbiome research. Determining the cause-effect relationships and designing microbiome-based therapies that can attain effective results on the human health and microbial community are among such challenges.

Several players, such as Sanofi S.A and Taisho Pharmaceuticals, are currently offering these microbiome therapeutics in the market. The entry of new players in the market, coupled with increased innovation pertaining to therapeutic output maximization with minimal side effects, has transformed the market currently.

The existing market of microbiome therapeutics is favored by multiple factors, which include the rising geriatric populations coupled with the increased financing and the increasing adoption of inorganic growth strategies by key players in the market.

Within the research report, the market is segmented on the basis of target therapy area (gastrointestinal and infectious diseases, and other diseases) and region (North America, Europe, Asia-Pacific, and Rest-of-the-World). This segmentation highlights value propositions and business models useful for industry leaders and stakeholders. The research also comprises country-level analysis, go-to-market strategies of leading players, future opportunities, among others, to detail the scope and provide a 360-coverage of the domain.

Competitive Landscape

Major players, including 4D Pharma, Enterome, and Finch Therapeutics, led the number of synergistic developments (partnerships and alliances) witnessed by the market. On the basis of region, Asia-Pacific is expected to retain a leading position throughout the forecast period 2020-2030, followed by Europe. This is a result of the presence of leading industry players in this region, coupled up with soaring clinical activities pertaining to the development of microbiome therapeutics.

Contents

Executive Summary

1 PRODUCT DEFINITION

1.1 Inclusion and Exclusion

2 MARKET SCOPE

2.1 Scope of Work

2.2 Key Questions Answered in the Report

3 RESEARCH METHODOLOGY

3.1 Global Microbiome Therapeutics Market: Research Methodology

3.2 Data Sources

3.3 Secondary Data Sources

3.4 Market Estimation Model

3.5 Criteria for Company Profiling

4 MARKET OVERVIEW

4.1 Market Size and Future Growth Potential

4.2 Historical Trends

5 INDUSTRY INSIGHTS

5.1 Regulatory Landscape

5.1.1 Regulatory Requirements for Live Biotherapeutic Products (LBPs)

5.2 Patent Landscape

5.2.1 Patent Filing Analysis

5.2.2 Key Players Patent Portfolio

5.2.3 Key Players Patent Expiration Analysis

5.3 Financing Landscape

5.3.1 Financing Stratification (as Per Raised Financing Value)

5.3.2 Year on Year Financing Analysis (FY2017-3Q2020)

5.3.3 Investment Heat Map

5.4 Pipeline Landscape

- 5.4.1 Competitive Landscaping
- 5.4.2 Pipeline Analysis
 - 5.4.2.1 By Developmental Phase
 - 5.4.2.2 By Route of Administration
 - 5.4.2.3 By Type of Microbiome Strategy
 - 5.4.2.4 By Target Therapy Area
- 5.5 Partnership Landscape
- 5.6 Government Initiatives

6 MARKET DYNAMICS

- 6.1 Market Drivers
 - 6.1.1 Significant External Funding for Executing Research and Therapeutic Innovation
 - 6.1.2 Increasing Adoption of Inorganic Growth Strategies in the Market
- 6.2 Market Restraints
 - 6.2.1 Payer Uncertainty and Outcome-Based Pricing
 - 6.2.2 Insufficient Application-Based Research Hindering Market Pull
 - 6.2.3 FMT Manufacturing Issues
- 6.3 Market Opportunities
 - 6.3.1 Entry of Major Players for the Development of Microbiome Therapeutics
 - 6.3.2 Growing Eminence of Microbiome Therapeutics in Cancer Treatment

7 COMPETITIVE INSIGHTS

- 7.1 Key Strategies and Developments
- 7.2 Synergistic Activities
- 7.3 Regulatory Accreditations
- 7.4 Mergers and Acquisitions
- 7.5 Market Share Analysis
- 7.6 Growth Share Analysis (Opportunity Mapping)
 - 7.6.1 By Geography
 - 7.6.2 By Company

8 GLOBAL MICROBIOME THERAPEUTICS MARKET (BY TARGET THERAPY AREA)

- 8.1 Overview
- 8.2 Gastrointestinal and Infectious Diseases
- 8.3 Other Diseases

9 GLOBAL MICROBIOME THERAPEUTICS MARKET (BY REGION)

9.1 Overview

9.2 North America

9.2.1 Overview

9.2.2 U.S.

9.2.3 Canada

9.3 Europe

9.3.1 Overview

9.3.2 France

9.3.3 Sweden

9.3.4 Germany

9.3.5 U.K.

9.3.6 Rest-of-Europe

9.4 Asia-Pacific (APAC)

9.4.1 Overview

9.4.2 Japan

9.4.3 Australia

9.4.4 China

9.4.5 India

9.4.6 Rest-of-Asia-Pacific

9.5 Rest-of-the-World

9.5.1 Overview

10 COMPANY PROFILES

10.1.1 Overview

10.2 4D Pharma plc

10.2.1 Company Overview

10.2.2 Role of 4D Pharma plc in Global Microbiome Therapeutics Market

10.2.3 Financials

10.2.4 SWOT Analysis

10.3 AOBiome

10.3.1 Company Overview

10.3.2 Role of AOBiome in the Global Microbiome Therapeutics Market

10.3.3 SWOT Analysis

10.4 Finch Therapeutics

10.4.1 Company Overview

- 10.4.2 Role of Finch Therapeutics in Global Microbiome Therapeutics Market
- 10.4.3 SWOT Analysis
- 10.5 Ferring Pharmaceuticals
 - 10.5.1 Company Overview
 - 10.5.2 Rebiotix Inc. (A Subsidiary of Ferring Pharmaceuticals)
 - 10.5.3 Company Overview
 - 10.5.4 Role of Rebiotix Inc. in Global Microbiome Therapeutics Market
 - 10.5.5 SWOT Analysis
- 10.6 Immuron Limited
 - 10.6.1 Company Overview
 - 10.6.2 Role of Immuron in Global Microbiome Therapeutics Market
 - 10.6.3 Financials
 - 10.6.4 SWOT Analysis
- 10.7 MaaT Pharma
 - 10.7.1 Company Overview
 - 10.7.2 Role of MaaT Pharma in Global Microbiome Therapeutics Market
 - 10.7.3 SWOT Analysis
- 10.8 Naked Biome
 - 10.8.1 Company Overview
 - 10.8.2 Role of Naked Biome in Global Microbiome Therapeutics Market
 - 10.8.3 SWOT Analysis
- 10.9 OxThera AB
 - 10.9.1 Company Overview
 - 10.9.2 Role of OxThera AB in Global Microbiome Therapeutics Market
 - 10.9.3 SWOT Analysis
- 10.1 Quorum Innovations
 - 10.10.1 Company Overview
 - 10.10.2 Role of Quorum Innovations, LLC in Global Microbiome Therapeutics Market
 - 10.10.3 SWOT Analysis
- 10.11 Sanofi S.A.
 - 10.11.1 Company Overview
 - 10.11.2 Role of Sanofi S.A. in Global Microbiome Therapeutics Market
 - 10.11.3 Financials
 - 10.11.4 Key Insights About the Financial Health of the Company
 - 10.11.5 SWOT Analysis
- 10.12 Seres Therapeutics, Inc.
 - 10.12.1 Company Overview
 - 10.12.2 Role of Seres Therapeutics, Inc. in Global Microbiome Therapeutics Market
 - 10.12.3 Financials

- 10.12.4 Key Insights About Financial Health of the Company
- 10.12.5 SWOT Analysis
- 10.13 Synthetic Biologics
 - 10.13.1 Company Overview
 - 10.13.2 Role of Synthetic Biologics, Inc. in Global Microbiome Therapeutics Market
 - 10.13.3 Financials
 - 10.13.4 SWOT Analysis
- 10.14 Taisho Pharmaceutical
 - 10.14.1 Company Overview
 - 10.14.2 Biofermin Pharmaceutical Co. Ltd. (A Subsidiary of Taisho Pharmaceutical)
 - 10.14.3 Company Overview
 - 10.14.4 Role of Taisho Pharmaceutical in Global Microbiome Therapeutics Market
 - 10.14.5 Financial
 - 10.14.6 Key Insights about the Financial Health of the Company
 - 10.14.7 SWOT Analysis
- 10.15 Vedanta Biosciences, Inc.
 - 10.15.1 Company Overview
 - 10.15.2 Role of Vedanta Biosciences, Inc. in Global Microbiome Therapeutics Market
 - 10.15.3 SWOT Analysis
- 10.16 Pendulum Therapeutics
 - 10.16.1 Company Overview
 - 10.16.2 Role of Pendulum Therapeutics in Global Microbiome Therapeutics Market
 - 10.16.3 SWOT Analysis

List Of Tables

LIST OF TABLES

Table 5.1: Global Microbiome Therapeutics Market (Key Players Patent Portfolio)

Table 5.2: Patent Expiration Analysis

Table 5.3: Key Players Investors Portfolio

Table 5.4: Key Players Investors Portfolio

Table 5.5: Partnership Landscaping

Table 5.6: Government Initiatives in Microbiome Therapeutics

Table 6.1: Microbiome Collaborations

Table 9.1: EU Funding of Microbiome Research Under FP7 and H2020

List Of Figures

LIST OF FIGURES

Figure 1: Impact Analysis of Market Drivers and Market Challenges on Global Microbiome Therapeutics Market

Figure 2: Global Microbiome Therapeutics Market (by Target Therapy Area), \$Million, 2020 and 2030

Figure 3: Global Microbiome Therapeutics Market (by Region), \$Million, 2019-2030

Figure 2.1: Global Microbiome Therapeutics Market Segmentation

Figure 3.1: Global Microbiome Therapeutics Market Research Methodology

Figure 3.2: Primary Research Methodology

Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)

Figure 3.4: Top-Down Approach (Segment-Wise Analysis)

Figure 4.1: Global Microbiome Therapeutics Market, \$Million, 2019-2030

Figure 4.2: Historical Evolution of Microbiome

Figure 5.1: Chemistry, Manufacturing, and Control (CMC) Information of LBPs by FDA

Figure 5.2: Patent Landscape of Microbiome Therapeutics Market (by Company and Region)

Figure 5.3: Key Players Financing Stratification

Figure 5.4: Financing Analysis, \$Million, FY2017-3Q2020

Figure 5.5: Number of Pipeline Candidates (by Developmental Phase)

Figure 5.6: Number of Pipeline Candidates (by Route of Administration)

Figure 5.7: Number of Pipeline Candidates (by Type of Product)

Figure 5.8: Number of Pipeline Candidates (by Target Therapy Area)

Figure 6.1: Market Dynamics of Global Microbiome Therapeutics Market

Figure 6.2: Financing Activities Breakout, 2017-2019

Figure 6.3: Overall Financing Raised by Microbiome Companies, \$Million, January 2017 – 3Q 2020

Figure 6.4: Synergistic Activities, 2017-2019

Figure 7.2: Synergistic Activities Share (by Company), January 2017-October 2020

Figure 7.3: Accreditations Share (by Company), January 2017- October 2020

Figure 7.4: Mergers and Acquisitions (by Company), January 2017- October 2020

Figure 7.5: Market Share Analysis for the Global Microbiome Therapeutics Market, 2018 and 2019

Figure 7.6: Growth Share Analysis (by Geography)

Figure 7.7: Growth Share Analysis (by Company)

Figure 8.1: Global Microbiome Therapeutics Market (by Target Therapy Area), 2020 and 2030

Figure 8.2: Number of Pipeline Candidates for Gastrointestinal and Infectious Diseases Indications

Figure 8.3: Global microbiome therapeutics market (Gastrointestinal and Infectious Diseases), 2019-2030

Figure 8.4: Global Microbiome Therapeutics Market (Other Diseases), 2023-2030

Figure 9.1: Global Microbiome Therapeutics Market (by Region), 2020 and 2030

Figure 9.2: North America Microbiome Therapeutics Market, 2019-2030

Figure 9.3: North America: Market Dynamics

Figure 9.4: North America Microbiome Therapeutics Market (by Country), 2020 and 2030

Figure 9.5: U.S. Microbiome Therapeutics Market, 2019-2030

Figure 9.6: Canada Microbiome Therapeutics Market, 2019-2030

Figure 9.7: Europe Microbiome Therapeutics Market, 2019-2030

Figure 9.8: Europe: Market Dynamics

Figure 9.9: Europe Microbiome Therapeutics Market (by Country), 2020 and 2030

Figure 9.10: France Microbiome Therapeutics Market, 2019-2030

Figure 9.11: Sweden Microbiome Therapeutics Market, 2019-2030

Figure 9.12: Germany Microbiome Therapeutics Market, 2019-2030

Figure 9.13: U.K. Microbiome Therapeutics Market, 2019-2030

Figure 9.14: Rest-of-Europe Microbiome Therapeutics Market, 2019-2030

Figure 9.15: Asia-Pacific Microbiome Therapeutics Market, 2019-2030

Figure 9.16: Asia-Pacific: Market Dynamics

Figure 9.17: Asia-Pacific Microbiome Therapeutics Market (by Country), 2020 and 2030

Figure 9.18: Japan Microbiome Therapeutics Market, 2019-2030

Figure 9.19: Australia Microbiome Therapeutics Market, 2019-2030

Figure 9.20: China Microbiome Therapeutics Market, 2019-2030

Figure 9.21: India Microbiome Therapeutics Market, 2019-2030

Figure 9.22: Rest-of-Asia-Pacific Microbiome Therapeutics Market, 2019-2030

Figure 9.23: Rest-of-the-World Microbiome Therapeutics Market, 2019-2030

Figure 10.1: Total Number of Companies Profiled

Figure 10.2: 4D Pharma plc: Overall Product Portfolio

Figure 10.3: 4D Pharma plc.: Overall Financials, 2018-2019

Figure 10.4: 4D Pharma plc: SWOT Analysis

Figure 10.5: AOBiome.: Overall Product Portfolio

Figure 10.6: AOBiome: SWOT Analysis

Figure 10.7: Finch Therapeutics: Overall Product Portfolio

Figure 10.8: Finch Therapeutics: SWOT Analysis

Figure 10.9: Rebiotix Inc.: Overall Product Portfolio

Figure 10.10: Rebiotix Inc.: SWOT Analysis

- Figure 10.11: Immuron: Overall Product Portfolio
- Figure 10.12: Immuron: Overall Financials, 2018-2020
- Figure 10.13: Immuron: Research and Development Expenditure, 2018-2020
- Figure 10.14: Immuron: SWOT Analysis
- Figure 10.15: MaaT Pharma.: Overall Product Portfolio
- Figure 10.16: MaaT Pharma: SWOT Analysis
- Figure 10.17: Naked Biome: Overall Product Portfolio
- Figure 10.18: Naked Biome: SWOT Analysis
- Figure 10.19: OxThera AB: Overall Product Portfolio
- Figure 10.20: OxThera AB: SWOT Analysis
- Figure 10.21: Quorum Innovations, LLC: Overall Product Portfolio
- Figure 10.22: Quorum Innovations, LLC: SWOT Analysis
- Figure 10.23: Sanofi S.A.: Overall Product Portfolio
- Figure 10.24: Sanofi S.A.: Overall Financials, 2017-2019
- Figure 10.25: Sanofi S.A.: Revenue (by Segment), 2017-2019
- Figure 10.26: Sanofi S.A.: Region Revenue, 2017-2019
- Figure 10.27: Sanofi S.A.: Research and Development Expenditure, 2017-2019
- Figure 10.28: Sanofi S.A.: SWOT Analysis
- Figure 10.29: Seres Therapeutics, Inc.: Overall Product Portfolio
- Figure 10.30: Seres Therapeutics, Inc.: Overall Financials, 2017-2019
- Figure 10.31: Seres Therapeutics Inc.: R&D Expenditure, 2017-2019
- Figure 10.32: Seres Therapeutics Inc.: SWOT Analysis
- Figure 10.33: Synthetic Biologics, Inc.: Overall Product Portfolio
- Figure 10.34: Synthetic Biologics, Inc.: Overall Financials, 2017-2019
- Figure 10.35: Synthetic Biologics, Inc.: SWOT Analysis
- Figure 10.36: Taisho Pharmaceutical Co., Ltd.: Overall Product Portfolio
- Figure 10.37: Taisho Pharmaceutical Co., Ltd.: Overall Financials, 2017-2019
- Figure 10.38: Taisho Pharmaceutical Co., Ltd. (by Segment), 2017-2019
- Figure 10.39: Taisho Pharmaceutical Co., Ltd. (by Region), 2019
- Figure 10.40: Taisho Pharmaceutical Co., Ltd.: R&D Expenditure, 2018-2019
- Figure 10.41: Taisho Pharmaceutical Co., Ltd.: SWOT Analysis
- Figure 10.42: Vedanta Biosciences, Inc.: Overall Product Portfolio
- Figure 10.43: Vedanta Biosciences, Inc.: SWOT Analysis
- Figure 10.44: Whole Genome Inc.: Overall Product Portfolio
- Figure 10.45: Whole Biome Inc.: SWOT Analysis

I would like to order

Product name: Global Microbiome Therapeutics Market: Focus on Target Therapies, Region (10 Countries), and Competitive Landscape - Analysis and Forecast, 2019-2030

Product link: <https://marketpublishers.com/r/GB204D360582EN.html>

Price: US\$ 5,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GB204D360582EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

